Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Q3 2020 Earnings Presentation

23 slides from Eurofins Scientific's earnings presentation, Oct 22, 2020

  1. Slide 1: Q3 / First Nine Months 2020 Management Update

    Q3 / First Nine Months 2020 Management Update 22 October 2020 www.eurofins.com

  2. Slide 2: Disclaimer

    Disclaimer The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain

  3. Slide 3: Agenda – Q3/NM 2020 Results Presentation

    Agenda – Q3/NM 2020 Results Presentation ▪ Q3/NM Financial Highlights ▪ Business Review ▪ Outlook ▪ Q&A ▪ Appendix 3

  4. Slide 4: Q3/NM 2020 Financial Highlights

    Q3/NM 2020 Financial Highlights Q3 2020 Reported Revenues €1,413m +21.0% yoy +22.7% organic growth (OG) +21.9% OG corrected for cyber-attack & fires NM 2020 Reported Revenues €3,736m +12.0% yoy +11.1% organic growth +9.0% OG corrected for cyber-attack & fires Successful refinancing of the Schuldsche

  5. Slide 5: Q3/NM 2020 Business Highlights

    Q3/NM 2020 Business Highlights Eurofins’ end markets proved to be very resilient once again ➢ In spite of continued COVID-19 pandemic related business disruptions, Eurofins core business* returned to small positive organic growth in Q3 2020 ➢ Many of Eurofins’ core businesses* across Food, Environme

  6. Slide 6: Agenda – Q3/NM 2020 Results Presentation

    Agenda – Q3/NM 2020 Results Presentation ▪ Q3/NM Financial Highlights ▪ Business Review ▪ Outlook ▪ Q&A ▪ Appendix 6

  7. Slide 7: COVID-19 related business developments (1/3)

    COVID-19 related business developments (1/3) Over 900 contracts signed since the launch of the programme on 29/05/2020, another 1,100 agreements under negotiation including some very large global contracts Eurofins is a key provider of COVID-19 testing. Some examples include: • Testing for the Nethe

  8. Slide 8: COVID-19 related business developments (2/3)

    COVID-19 related business developments (2/3) Eurofins U.S. Clinical Diagnostics launched FDA EUA1-authorised At- Home COVID-19 Nasal PCR test • Self-collection kit gives consumers painless, convenient and quick option to detect the virus from the comfort of their home • Results provided via email wi

  9. Slide 9: COVID-19 related business developments (3/3)

    COVID-19 related business developments (3/3) Eurofins scientists published robust method1 to analyse SARS-CoV-2 in wastewater samples • Offered as part of Eurofins COVID-19 Sentinel™ programme, wastewater testing allows for early detection of COVID-19 presence at a given site, before the virus sprea

  10. Slide 10: Core business Q3 2020 developments

    Core business Q3 2020 developments ➢ Eurofins Discovery expanded its chemistry capacity to serve customer demand in the growing market of outsourced drug discovery with a new building nearing completion at Eurofins Discovery’s flagship chemistry site at Eurofins Villapharma in Murcia, Spain ➢ Eurofi

  11. Slide 11: Q3/NM 2020 M&A update

    Q3/NM 2020 M&A update After achieving this position in Europe, Eurofins became the market leader in non- invasive prenatal testing (NIPT) in Japan with the acquisition of GeneTech Inc. • a leading player in genetic analysis in Japan with over €10m revenues in 2019 Eurofins became the market leader i

  12. Slide 12: Agenda – Q3/NM 2020 Results Presentation

    Agenda – Q3/NM 2020 Results Presentation ▪ Q3/NM Financial Highlights ▪ Business Review ▪ Outlook ▪ Q&A ▪ Appendix 12

  13. Slide 13: Eurofins' 5-year investment programme update

    Eurofins’ 5-year investment programme update Eurofins has achieved leading market positions: ➢ Global leader in fast growing Environment, Food, BioPharma & Cosmetics Products Testing ➢ Leading start-up position in several promising niches • Strong global position in Molecular & Genomics Clinical Tes

  14. Slide 14: Eurofins 2022 objectives

    Eurofins 2022 objectives (excluding any COVID-19 testing & reagents revenues or successor multi pathogens clinical testing) Based on leading market positions already achieved: ➢ Eurofins is setting new objectives for 2022 and beyond (at constant FX rates as of 30/09/2020): • €5.7bn revenues with cor

  15. Slide 15: New objective to achieve €5.7bn reported revenues in 2022

    New objective to achieve €5.7bn reported revenues in 2022 Illustration of Eurofins’ 2020-2022 revenues objectives 2020 and 2021 objectives are left unchanged for now due to uncertainty on COVID-19 pandemic evolution and may be significantly exceeded 2022 objective assumes no COVID-19 clinical testin

  16. Slide 16: Outlook

    Outlook ➢ Given the uncertainty on the net impact of the COVID-19 pandemic in 2020 & 2021, it was decided to leave objectives for those two years unchanged for now (2020-21 objectives were set before onset of the COVID-19 pandemic at constant average 2019 FX rates) ➢ 2022 should hopefully be the fir

  17. Slide 17: Conclusion

    Conclusion Eurofins’ financial performance is concrete evidence of the Group’s positioning in attractive end markets, agility and adaptability, as well as results of years of investments to build a network of state-of-the-art laboratories and leading R&D teams: ➢ Exceeded 22% organic growth in Q3 20

  18. Slide 18: Q&A

    Agenda – Q3/NM 2020 Results Presentation Q&A 18

  19. Slide 19: Agenda – Q3/NM 2020 Results Presentation

    Agenda – Q3/NM 2020 Results Presentation ▪ Q3/NM Financial Highlights ▪ Business Review ▪ Outlook ▪ Q&A ▪ Appendix 19

  20. Slide 20: Eurofins accounting practices are in line with its more mature TICS peers

    Eurofins accounting practices are in line with its more mature TICS peers and the Business Services industry Credit Suisse research – Accounting Scorecard Breakdown (Score 0-10, best score = 10) 9 8 7 6 5 4 3 2 1 0 Scorecard Auditor focus Pension deficit Debtor days Accrued/Deferred FCF to Equity Av

  21. Slide 21: Revenues bridge 2019-2022, without COVID-19 impacts

    Revenues bridge 2019-2022, without COVID-19 impacts* Objectives* 2020-2021 revenues will in reality be different: • Higher due to COVID-19 testing & reagents revenues (€bn) • Lower due to lockdowns and travel/eat-out restrictions 6.0 + - €5.7bn* 5.5 30/09/2020 FX negative impact of €0.12bn 5.0 4.5 €

  22. Slide 22: Free Cash Flow to the Firm (FCFF): 2020, 2021 and 2022 objectives

    Free Cash Flow to the Firm (FCFF): 2020, 2021 and 2022 objectives* Objectives* (€m) 850 FY 2019 FY 2020*** FY 2021*** FY 2022 €800m 800 750 €700m** 700 650 €600m** 600 550 500 €478m** 450 400 350 FCFF CAPEX Δ NWC Cyber-attack Profit growth FCFF CAPEX Δ NWC Cyber-attack Profit growth FCFF CAPEX Δ NWC

  23. Slide 23: Definitions / Alternative Performance Measures (APMs)

    Definitions / Alternative Performance Measures (APMs) Eurofins is providing in the Income Statement certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results – reflect the ongoing performance of the mature and recurring activitie

Eurofins Scientific — Q3 2020 Earnings Presentation on 6ix